Company ProfilePremium

Auro Laboratories Limited

Company Profile Analysis

Ticker: 530233.BO

ESOMAR 23 Corporate BadgeISO Certifications Badge
Auro Laboratories Limited - Company showcase

Year Founded & Workforce

1992

Auro Laboratories Limited logo

Auro Laboratories Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Auro Laboratories Limited Overview

Auro Laboratories is a single-site, promoter-controlled Indian micro-cap manufacturing generic active pharmaceutical ingredients from MIDC Tarapur, Maharashtra, with an overwhelming concentration in Metformin Hydrochloride — the first-line oral therapy for type 2 diabetes — which Crisil estimated contributes nearly 80% of revenue. The company holds European Certificates of Suitability (CEPs) for Metformin HCl and Chlorphenamine Maleate, EU-GMP and WHO-GMP accreditation, and exports roughly 70–75% of output to Europe, South-East Asia, the Middle East, Africa and Latin America. Between FY2024 and FY2026 it executed a debt-funded brownfield expansion that shut the legacy unit for about nine months, collapsing FY2025 revenue by roughly 64%, before a partial recovery in FY2026. Management now markets an enlarged metformin capacity, direct-compression granules and a new finished-dose (FDF) tablet line for metformin combinations with gliptins and gliflozins. The equity story is a leveraged volume ramp-up bet: a sharply larger asset base, net debt above INR 600 million, and a sub-scale revenue line that must now catch up.


What the company does. Auro Laboratories manufactures and sells bulk drugs (APIs), pharmaceutical intermediates and, increasingly, value-added downstream forms of its core molecule. Its historical self-description, repeated across its website, exchange profiles and trade-show listings, positions it as an API, intermediates and generic formulations maker founded in Mumbai with a plant at Tarapur about 120 km from the city, whose primary focus is anti-diabetic drugs — specifically Metformin HCl and the sulfonylurea Glibenclamide — complemented by toll/custom manufacturing of APIs and intermediates on a contract basis. In 2026 trade-show profiles (CPHI Milan, CPHI India, CPHI Middle East, CPHI Korea, CPHI South-East Asia) the company describes itself more broadly as a manufacturer of APIs, direct compression (DC) granules and finished dosage forms, citing an expanded metformin capacity and a newly added tablet facility.

Business model. The model is a classic merchant-API business: Auro buys key starting materials and reagents (a material portion imported from overseas vendors per Acuite, April 2026), runs multi-step chemical synthesis and crystallisation at Tarapur, and sells pharmacopoeial-grade API in bulk to generic finished-dose manufacturers who hold the marketing authorisations. Regulatory dossiers (CEPs; country registrations in South Korea, Malaysia, Taiwan, Iran, Egypt and Bangladesh per the company's CPHI China profile) are the commercial "licence to sell" into each market. Value is captured through cost per kilogram, yield, consistency and regulatory acceptability rather than brand.

Revenue model mix. Product sales dominate. Toll/custom manufacturing and "regulatory services" are listed offerings but their revenue share is not publicly disclosed. There is no subscription or licensing revenue. An approximate mix based on available disclosures:

Value-chain position. Upstream of finished-dose generic manufacturers; downstream of commodity chemical suppliers (dimethylamine hydrochloride / dicyandiamide-type inputs for metformin — specific inputs not disclosed by the company). Auro is not backward-integrated into key intermediates, unlike its largest Indian peer Aarti Drugs, which commissioned a dedicated amines facility in FY2026 to self-supply metformin intermediates (Aarti Drugs Q2 and Q3 FY2026 disclosures). The FDF move represents Auro's first meaningful forward integration.

Customer types. Generic formulators in regulated (EU) and semi-regulated/emerging markets; Crisil notes a large client base, and Acuite notes established customers across Europe and South-East Asia. No single-customer concentration figures are publicly disclosed. Credit terms of 60–90 days are extended to major clients (Crisil, Aug 2025).

Independent characterisation. Auro is best understood as a sub-scale, single-product metformin specialist that has just made a capital commitment roughly four times its pre-expansion fixed-asset base (gross PP&E rose from INR 172.8 million in FY2022 to INR 896.7 million in FY2026, S&P data). Its competitive moat rests on regulatory credentials (CEP, EU-GMP via Swissmedic per company profile, WHO-GMP valid to September 2028) rather than scale or cost leadership. The business is a price-taker in a globally commoditised molecule whose market price tracks raw-material costs (Vistin Pharma Q3/Q4 2025 commentary), so the investment case hinges on capacity utilisation and the success of higher-value DC granules and FDF combinations.

Strategy

Stated strategy themes (paraphrased from company profiles and rating rationales; no investor-day or earnings call exists).

  1. Anti-diabetic focus: concentrate on the diabetes therapeutic area, which management has long described as among the fastest-growing segments, with metformin as the anchor and additional anti-diabetic molecules "on the anvil."

  2. Scale in metformin: expand metformin capacity (brownfield expansion completed 2025) to move from a niche supplier to a meaningful-volume producer.

  3. Move up the value chain: add DC granules, combination granules (metformin + gliptins/gliflozins) and a finished-dose tablet facility (1 billion tablets p.a.).

  4. Regulated-market credentials: maintain CEPs, EU-GMP (Swissmedic per company profile) and WHO-GMP; extend country registrations.

  5. Patent-expiry pipeline: develop new APIs to launch on patent expiry (molecules undisclosed).

  6. International marketing: intensive CPHI participation across six regional events in 2026.

Strategic initiatives — last 24 months

Medium-term guidance. Management provides no formal financial guidance. The only forward-looking quantification is Acuite's expectation (April 2026) of net cash accruals of INR 6–15 crore over FY2026–FY2027 against repayment obligations of INR 2–6 crore over the same period.

Products & Services

Because Auro reports one segment, the catalogue is organised by therapeutic/product family. Pricing is not publicly disclosed for any product; for context, QYResearch (Oct 2025) estimates the 2024 average global metformin HCl API price at roughly US$5,894 per MT.

Anti-diabetic franchise (core)

ProductDescription & capabilitiesRegulatory credentialsTarget customerLaunch / latest statusNotes
Metformin Hydrochloride API (flagship)Biguanide; first-line type 2 diabetes therapy. Capacity claims vary: >500 TPA (legacy site text), 1,800 MTPA expanding to 3,600 MTPA (IIFL summary), 1,260 → 2,100 MT p.a. total plant (Acuite, Apr 2026), and 7,200 MT/yr metformin (company CPHI 2026 profiles)CEP (EDQM) since Sep 2006; EU-GMP; WHO-GMP valid to Sep 2028; USDMF listed by PharmaOfferGeneric tablet makers in EU, SE Asia, Middle East, Africa, LatAmExpansion completed 2025; new block commissioned Aug 2025~80% of revenue (Crisil). Capacity discrepancy flagged in Section 8
Metformin Direct Compression (DC) GranulesReady-to-compress metformin granules that let formulators skip wet granulation; higher value-add than plain APINot publicly disclosed (DC grade dossiers)Formulators seeking process simplificationMarketed in 2026 CPHI profilesCompetes with Vistin Pharma and Wanbury DC grades
Metformin combination granules (with gliptins and gliflozins)Fixed-dose combination granules pairing metformin with DPP-4 inhibitors ("gliptins") and SGLT2 inhibitors ("gliflozins"); specific molecules not named—FDC formulators, esp. India and emerging markets2026 (company profiles)Strategic diversification lever
Finished Dosage Forms — Metformin tablets & combinationsNew FDF facility, stated capacity 1 billion tablets p.a.; metformin single-agent and combinations with gliptins/gliflozins—B2B supply / contract supply; domestic and export2026 (company profiles)First forward integration; revenue not disclosed
Glibenclamide (Glyburide)Second-generation sulfonylurea; listed both as API (website) and intermediate (CPHI)USDMF listed by PharmaOfferGeneric formulatorsLegacy productSmall, undisclosed contribution
GlimepirideThird-generation sulfonylureaUSDMF listed by PharmaOfferGeneric formulatorsListed 2025–2026Status of commercial volumes not disclosed
GlipizideSecond-generation sulfonylureaUSDMF listed by PharmaOfferGeneric formulatorsListed 2025–2026Status of commercial volumes not disclosed

Non-diabetic APIs

ProductDescriptionCredentialsTarget customerStatus
Chlorphenamine (Chlorpheniramine) MaleateFirst-generation antihistamine used in cold/allergy combinationsCEP (EDQM)OTC and cough/cold formulatorsKey secondary product
ChlorzoxazoneCentrally acting muscle relaxantWritten confirmation (WC) listed by PharmaOfferAnalgesic/muscle relaxant formulatorsKey secondary product (Screener lists as key API)
Desmopressin; OctreotidePeptide APIs listed with CEP on PharmaOfferpossibly a directory error or traded products——
Other listed moleculesDiuretic, iron-deficiency, antifungal, anti-ulcer, antimalarial, anti-inflammatory, analgesic, antacid APIs; potassium iodide and sodium iodide; microcrystalline cellulose (excipient)—VariousListed by Simply Wall St description

Services

ServiceDescriptionStatus
Toll / custom manufacturing (CDMO)Contract manufacture of APIs and intermediates using Auro's reactorsLong-standing offering; revenue not disclosed
Regulatory servicesDossier support for customers' registrationsListed on PharmaSource directory; revenue not disclosed
Pipeline APIs "on patent expiry"New products under development to be offered when patents lapseNamed molecules not disclosed (CPHI China profile)

Financial Narrative

Basis: S&P Global Market Intelligence standardised standalone data (StockAnalysis.com, updated 14 Aug 2026), INR million, FY ending 31 March. EBITDA = operating income + depreciation & amortisation (analyst computation). EPS computed on ~6.233 million shares (matches reported FY2025 EPS of INR 2.95 and FY2026 EPS of INR 5.67 per Screener/Fyers).

Margins and growth

Revenue CAGR FY2022–FY2026 (4 years): -11.8% per year. Revenue at FY2026 (INR 307.4 million) remains ~43% below the FY2024 peak (INR 536.35 million).

Commentary — income statement. Three regimes are visible. FY2022–FY2023 was a stable, low-margin commodity phase: revenue ~INR 510–530 million with EBITDA margins of 8–9%, squeezed by freight and raw-material inflation that Crisil notes could not be passed through promptly (operating margins volatile in a 10–23% band through FY2025). FY2024 was an inflection: gross margin jumped to ~50% on softer input costs, foreign-exchange gains of INR 14.3 million, and better realisations, lifting net income to a record INR 77.9 million (PAT margin 14.5%). FY2025 was the expansion trough: the legacy unit was shut for about nine months to integrate with the new block (Crisil; Acuite), cutting revenue 64% to INR 191 million; profitability held up better than revenue because cost of revenue fell proportionately and other income (INR 7.8 million) cushioned the bottom line. FY2026 is the early ramp: revenue recovered 61% to INR 307 million and operating margin reached 24%, but Acuite notes 9MFY2026 revenue of INR 22.25 crore was below expectations owing to Middle East geopolitical disruption. Interest expense quadrupled to INR 39.6 million as capitalisation of borrowing costs ceased post-commissioning, and depreciation rose 2.6× to INR 28.1 million — together absorbing ~65% of the EBITDA gain.

Data-quality flag (FY2026 gross margin). A 79% gross margin is anomalous for a merchant-API business; the S&P cost-of-revenue line (INR 63.3 million) appears to exclude inventory build (inventory rose INR 98.7 million in FY2026) or classify certain manufacturing costs in "other operating expenses" (INR 69.6 million). EBITDA margin (33%) aligns with Acuite's ~31% 9MFY2026 operating margin, so EBITDA is the more reliable profitability measure.

Quarterly trajectory (INR crore; standalone)

Sources: Business Standard/Capital Market for Q1FY25, Q2FY25, Q1FY26, Q2FY26 sales and all net profits; Q3FY25, Q4FY25, Q3FY26, Q4FY26 and Q1FY27 revenues are analyst derivations (from reported YoY growth, net-margin disclosures on Bajaj Broking, and annual totals) and should be verified against Regulation 33 filings. Discrepancies: (a) FY2025 quarterly net profits sum to INR 1.55 crore versus the audited annual PAT of INR 1.84 crore — likely Q4 adjustments or restatement; (b) ScanX reported a Q2 FY2026 "loss of INR 71.58 lakh," conflicting with Business Standard, HDFC Sky and Bajaj Broking, which all show a profit of INR 0.72 crore; the profit figure is adopted as the majority-source reading; (c) Q1 FY2025 revenue is INR 5.72 crore (Business Standard) versus INR 5.92 crore (INDmoney). Q2 FY2026 operating margin was 26.58% (vs. 23.23% in Q2 FY2025).

Run-rate observation. The last four reported quarters (Q2FY26–Q1FY27) imply TTM revenue of ~INR 36.7 crore and TTM PAT of ~INR 4.69 crore. Quarterly revenue has plateaued in an INR 8.8–9.7 crore band for four consecutive quarters — roughly INR 35–39 crore annualised, still ~30% below FY2024's INR 53.6 crore despite a materially larger plant.

Balance sheet

Commentary — balance sheet. The balance sheet has been transformed from a lightly geared trading-style profile (FY2023 debt/equity 0.19×, INR 124 million of liquid assets in FY2022) to a leveraged manufacturing platform. Land was acquired in FY2024 (land line rose from INR 0.44 million to INR 103.19 million), buildings rose five-fold to INR 225 million in FY2026, and machinery rose from ~INR 213 million to INR 562 million on capitalisation of the new block. Debt has been the dominant funding source — total debt rose ~10× from FY2023 to FY2026 while equity rose only ~36% (entirely from retained earnings). Fund-based working-capital limits were near-fully utilised (Crisil). Working capital turned negative in FY2025 and is only marginally positive in FY2026; Crisil assessed liquidity as "stretched" in August 2025, while Acuite (April 2026) termed it "adequate," a divergence that reflects timing and the larger sanctioned limits.

Cash flow

Commentary — cash flow. Cumulative FY2022–FY2026 free cash flow is approximately -INR 1,026 million, funded by ~INR 602 million of net new debt, the FY2022 liquid-asset cushion, and an unexplained INR 419.9 million "sale of property, plant & equipment" line in FY2026. That FY2026 inflow is not explained in any disclosure reviewed; it may represent a reclassification of capital work-in-progress, a capital subsidy, or a sale-and-leaseback, and is the single most important item to verify in the FY2026 annual report. Net of it, FY2026 investing outflow was INR 147.9 million. Operating cash flow deteriorated to INR 21.1 million in FY2026 because inventory was rebuilt by INR 98.7 million to feed the new capacity. No dividends have been paid in five years despite profits (Screener flags this).

Ratios

FY2026 DIO and CCC are distorted by the anomalous cost-of-revenue classification noted in 6.2 and are not economically meaningful; on a revenue basis FY2026 inventory equals ~161 days of sales. Rating-agency equivalents: Crisil/Acuite report adjusted debt/net worth of 1.05× (FY2025) vs. 0.63× (FY2024), and PBDIT/interest of 3.75× (FY2025) vs. 16.55× (FY2024); Crisil reports gross current assets of 400–405 days at 31 March 2025 vs. ~195 days a year earlier, with receivables of 175–180 days and inventory of 85–90 days. Screener showed debtor days of 177 for FY2025.

Commentary — ratios. Every capital-efficiency metric peaked in FY2024 and has since deteriorated as the asset base outran revenue. Asset turnover has collapsed from ~0.9× to 0.25×; at FY2024's ~0.63× asset-turnover-on-enlarged-base, the plant would need to generate ~INR 760 million of revenue — about 2.5× FY2026 — to restore historical efficiency. Interest coverage below 2× and net debt/EBITDA of ~6× in FY2026 leave little margin for a further revenue miss; Crisil's own downgrade trigger was net cash accruals to repayment at or below 1.1×.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Results by Segment and Segment Margins & Growth (%)

MetricFY2022FY2023FY2024FY2025FY2026

Segment revenue — Bulk drugs/Pharma (INR Mn)

508.66528.94536.35191.24307.40

Segment operating income (INR Mn)

36.0833.1995.7820.3373.99

Segment pre-tax income excl. unusual items (INR Mn)

38.2834.46103.4618.8151.56

Segment operating margin (%)

7.16.317.910.624.1

Revenue YoY growth (%)

-6.243.991.40-64.3460.74

Contribution to total revenue (%)

100100100100100

Product Group Details

Product groupFY2025 indicative share of revenue (%)

Metformin HCl

80

All other APIs and services

20

Income Statement and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Revenue (INR Mn)

508.66528.94536.35191.24307.40

Cost of revenue (INR Mn)

335.46360.69269.4992.8263.29

Gross profit (INR Mn)

173.19168.26266.8698.42244.11

SG&A (INR Mn)

62.4047.2151.4428.7472.40

Operating income (INR Mn)

36.0833.1995.7820.3373.99

Depreciation & amortisation (INR Mn)

10.1710.7410.9210.9628.10

EBITDA (INR Mn)

46.2543.93106.7031.29102.09

Interest expense (INR Mn)

5.497.306.6910.0139.63

Pre-tax income excl. unusual items (INR Mn)

38.2834.46103.4618.8151.56

Pre-tax income reported (INR Mn)

38.2834.46103.4618.8148.09

Net income (INR Mn)

28.4524.4277.9218.3935.33

EPS basic (INR)

4.563.9212.502.955.67

EPS diluted (INR)

4.563.9212.502.955.67

Dividend per share (INR)

00000

Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Gross margin (%)

34.031.849.851.579.4

Operating margin (%)

7.16.317.910.624.1

EBITDA margin (%)

9.18.319.916.433.2

Net margin (%)

5.64.614.59.611.5

Revenue growth YoY (%)

-6.243.991.40-64.3460.74

Net income growth YoY (%)

-60.38-14.15219.09-76.4092.14

Income Statement

MetricQ1FY25Q2FY25Q3FY25Q4FY25Q1FY26Q2FY26Q3FY26Q4FY26Q1FY27

Revenue (INR Cr)

5.723.103.077.512.778.849.399.748.77

Net profit (INR Cr)

0.750.360.050.39-0.110.721.950.971.05

Balance Sheet and Per-Share Data

MetricFY2022FY2023FY2024FY2025FY2026

Total assets (INR Mn)

549.60559.94857.33990.961,211.00

Cash & short-term investments (INR Mn)

123.9617.879.92013.67

Short-term debt incl. current LTD (INR Mn)

121.1544.0078.66119.29199.91

Long-term debt (INR Mn)

16.6220.13183.78330.85433.14

Total debt (INR Mn)

137.7864.13262.44450.14633.05

Net debt (INR Mn)

13.8246.26252.52450.14619.38

Shareholders' equity (INR Mn)

315.21342.01419.59429.68463.48

Goodwill & intangibles (INR Mn)

00000

Working capital (INR Mn)

174.98175.3169.19-7.7322.10

Net PP&E (INR Mn)

172.83202.83548.31775.34896.68

Construction in progress (INR Mn)

36.7576.68326.81564.75144.84

Inventory (INR Mn)

42.55117.5682.4036.68135.40

Trade receivables (INR Mn)

136.13124.05133.9293.9391.51

Book value per share (INR)

50.5854.8767.3268.9474.36

Cash Flow

MetricFY2022FY2023FY2024FY2025FY2026

Operating cash flow (INR Mn)

-65.9032.81188.0750.2021.13

Capital expenditure (INR Mn)

46.1040.74356.40238.01571.39

Free cash flow (INR Mn)

-112.00-7.93-168.33-187.81-550.26

Proceeds from asset sales (INR Mn)

0000.02419.91

Net debt issued (INR Mn)

106.19-73.64198.31187.71182.91

Dividends paid (INR Mn)

00000

Share buybacks (INR Mn)

00000

Cash interest paid (INR Mn)

8.267.306.6910.0139.63

Returns & Leverage Ratios (%) and Financial Ratios (x)

MetricFY2022FY2023FY2024FY2025FY2026

ROE on closing equity (%)

9.07.118.64.37.6

ROA on closing assets (%)

5.24.49.11.92.9

ROIC — NOPAT at 25% tax / (equity + net debt) (%)

8.26.410.71.75.1

Current ratio (x)

1.871.971.290.961.08

Debt / equity (x)

0.440.190.631.051.37

Net debt / EBITDA (x)

0.301.052.3714.396.07

Interest coverage — EBIT / interest (x)

6.574.5514.322.031.87

Asset turnover (x)

0.930.940.630.190.25

Days sales outstanding (days)

97.785.691.1179.3108.7

Days inventory outstanding on COGS (days)

46.3119.0111.6144.2780.9

Days payables outstanding on COGS (days)

52.9116.284.0244.3269.7

Cash conversion cycle (days)

91.188.4118.779.2619.9

Region (FY2025 Indicative) Overview

Region (FY2025 indicative)Share of revenue (%)Implied revenue (INR Cr)

Exports (all regions)

72.514.07

India (domestic)

27.55.33

Valuation Snapshot

MetricValueSource / date

Last close

INR 231.60

StockAnalysis, 19 Oct 2026

52-week high / low

INR 317 / INR 159

Screener.in (2026)

1-year return

+3% (Screener CAGR table) / +5.96% (ScanX)

2026 snapshots — dates differ

6-month return

-12.64%

ScanX, Oct 2026

3-year price CAGR

40%

Screener.in

5-year price CAGR

20%

Screener.in

10-year price CAGR

28%

Screener.in

Long-run reference

Promoter purchases at INR 5.80 (17 Dec 2013)

Trendlyne

Liquidity

Thin — e.g., 479 shares traded in a session (Nirmal Bang); 1,370 shares (MarketsMojo)

Various 2025–2026

Analyst coverage

0 analysts

Simply Wall St

Valuation Multiples

MultipleAuro LaboratoriesBasis

Market cap (INR Mn)

1,444

6.233 M shares

Enterprise value (INR Mn)

2,063
  • net debt INR 619.4 M (Mar 2026)

P/E — TTM (x)

30.8

TTM EPS INR 7.52 (Q2FY26–Q1FY27 PAT INR 4.69 cr)

P/E — FY2026 (x)

40.8

EPS INR 5.67

P/B (x)

3.11

BVPS INR 74.36 (Mar 2026)

EV/EBITDA — FY2026 (x)

20.2

EBITDA INR 102.1 M

EV/Sales — FY2026 (x)

6.7

Revenue INR 307.4 M

EV/Sales — TTM (x)

5.6

TTM revenue ~INR 367 M (derived)

Dividend yield (%)

0

No dividends

Capital Markets

ItemStatus

Dividend history (FY2022–FY2026)

Nil every year

Dividend policy

Not publicly disclosed (not mandatory below top-1,000 threshold)

Moody's / S&P / Fitch

Not rated

Domestic rating

Acuite BB+/Stable (LT) and A4+ (ST), Apr 2026; Crisil BB+/A4+ withdrawn Aug 2025

Debt maturity profile

Term loan from Indian Bank maturing 30 Sep 2032 (INR 31.90 crore as of Aug 2025); current portion of LTD INR 19.6 M at Mar 2026; Acuite projects repayments of INR 2–6 crore/yr in FY2026–FY2027; short-term working-capital lines INR 180.3 M (Mar 2026) roll annually

Analyst Conclusions

Management guidance. None issued; no earnings calls or investor presentations. The only third-party forward view is Acuite's expectation of INR 6–15 crore of annual cash accruals over FY2026–FY2027 against INR 2–6 crore of repayments.

Consensus. No sell-side coverage (0 analysts); no consensus estimates exist.

Bull case

  1. Operating leverage on a built plant: with capex largely complete (CWIP down to INR 145 M), each incremental rupee of revenue carries ~30%+ EBITDA margins (Q2–Q3 FY2026 evidence); returning only to FY2024 revenue of INR 53.6 crore would roughly double EBITDA and cut net debt/EBITDA toward ~3×.

  2. Mix upgrade: DC granules, metformin–gliptin/gliflozin combinations and a 1 bn-tablet FDF line move Auro from commodity API toward higher-value, stickier products, at a time when DPP-4/SGLT2 generics are proliferating.

  3. Credential moat at micro-cap scale: CEPs, EU-GMP and WHO-GMP (renewed to 2028) are hard for new entrants to replicate and give access to regulated customers who multi-source.

Bear case

  1. Revenue plateau and price deflation: quarterly revenue has stalled at ~INR 9–10 crore for four quarters while global metformin prices softened (Vistin), and Aarti/Wanbury are expanding volume and integration — Auro may be filling capacity only at lower prices.

  2. Balance-sheet fragility: EBIT/interest <2×, net debt/EBITDA ~6×, fully utilised working-capital lines and 400-day gross current assets leave little cushion; a further shortfall could trigger a downgrade below BB+.

  3. Disclosure and governance gaps: unexplained INR 419.9 M FY2026 asset-sale inflow, mid-term auditor change and a CFO exit, combined with no investor communication, raise the evidentiary bar for the ramp-up thesis; at ~31× TTM earnings and ~3× book, the stock already discounts success.

Key catalysts and monitorables (next 12 months)

Analyst verdict. Auro Laboratories is a credible but under-scaled metformin specialist that has bet its balance sheet on growing into a plant several times larger than the business it replaced. The evidence since commissioning is mixed. On the positive side, the new block is clearly more profitable: operating margins in the high-20s to low-30s percent through FY2026 compare with single digits before the expansion, the company returned to profitability within a quarter of start-up, and it has kept its regulatory licences intact, renewing WHO-GMP through 2028. Promoters hold just over half the equity with no pledges, and the sole lender has enlarged rather than curtailed facilities.

The difficulty is that revenue has not followed capacity. Four consecutive quarters at roughly INR 9–10 crore annualise to well under FY2024's INR 53.6 crore, while interest and depreciation have absorbed most of the EBITDA uplift and pushed coverage below 2×. Working capital remains extremely heavy, and the competitive backdrop has hardened: the category leader has internalised its key intermediate, a mid-size peer is winning US FDA and Middle East metformin business, and global prices have eased. Against this, the market values the company at roughly 31× trailing earnings and 20× FY2026 EBITDA — multiples that already assume a successful ramp.

Our synthesis is therefore "show me." The equity can work if quarterly revenue moves decisively into the mid-teens of crores with margins held, which would roughly halve leverage within two years and validate the FDF and granule strategy. Until then, the risk-reward is skewed by balance-sheet fragility, single-molecule exposure, illiquidity, and unresolved disclosure questions — chiefly the unexplained FY2026 asset-sale inflow and the vacant CFO role. Investors should anchor on the Q2 and Q3 FY2027 prints and the FY2026 annual report notes before underwriting the capacity story. This is an assessment of public information, not investment advice.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameTitleTenure / appointmentBackgroundFY2025 total compensation

Sharat Deorah (DIN 00230784)

Chairman & Managing Director; Promoter

Promoter-director since founding; re-appointed CMD at 35th AGM (28 Jun 2024)

~Three decades in pharma/API (Crisil; Acuite)

—

Siddhartha Deorah (DIN 00230796)

Whole-Time Director; Promoter

With company since 1 Aug 1999; re-appointed WTD 28 Jun 2024; retires by rotation & re-appointed at 36th AGM

Director of related entities Auro Impex Pvt Ltd, Auro Real Estate Pvt Ltd (AR 2009-10); signs most exchange filings

—

Kiran Kulkarni

Whole-Time Director

Re-appointed for 3 years (30 Jun 2026)

Not publicly disclosed (likely plant/technical)

—

Goverdhandas Aggarwal

Independent Director (as of Mar 2023)

On board since at least 2009-10

—

Sitting fees — not disclosed

Kailash Chandra Bubna

Independent Director (as of Mar 2023); historic Audit Committee Chair

On board since at least 2009-10

—

Sitting fees — not disclosed

Kavita Vijayakant Sharma

Non-Executive Independent Director

Since 27 Mar 2015; second term 11 Feb 2026–10 Feb 2031

10+ years in marketing

Sitting fees — not disclosed

Vishal Kailash Chandra Jhunjhunwala

Independent Director (as of Mar 2023)

——

Sitting fees — not disclosed

Padma Tapariya

Company Secretary & Compliance Officer

From 1 Oct 2025

Associate member ICSI; ~7 years' experience

—

Chief Financial Officer

Vacated

Previous CFO resigned effective 28 May 2026; successor not identified in sources reviewed

——

“—” = not publicly disclosed.

Governance Overview

AttributeStatus

Board size

~7 (3 executive, ~4 independent as of Mar 2023); current composition after 2024–2026 changes not fully verified

Chair/CEO separation

No — Sharat Deorah is both Chairman and MD

Independent directors

~4 of 7 (≥50%, meeting SEBI requirement where chair is executive)

Women on board

1 (Kavita Sharma)

Committees

Audit Committee (historically chaired by K.C.

Long-tenured independents

Two independents appear on the 2009-10 board and were still listed in 2023; under the Companies Act 2013, IDs are limited to two consecutive five-year terms from 2014. Current status should be checked against the FY2026 annual report

Board & Management Changes

DateChangeContext

28 Jun 2024

CMD and WTD re-appointments approved

Routine renewal

14 Aug 2025

Company Secretary resignation disclosed

Replaced by Padma Tapariya, 1 Oct 2025

23 Aug 2025

Statutory auditor resignation; new auditor

Outgoing auditor cited pre-occupation; confirmed no disagreements with management

28 May 2026

CFO resignation

Occurred the day before FY2026 results approval; successor not disclosed — a governance monitorable

30 Jun 2026

Kiran Kulkarni re-appointed WTD (3 years)

Continuity of technical leadership

Major Shareholders

HolderCategorySharesStake (%)

Auro Impex Private Ltd

Promoter group

1,168,78118.75

Sharat Deorah

Promoter

1,165,80018.71

Siddhartha Deorah

Promoter group

441,6507.09

Samridhi Deorah

Promoter group

241,1913.87

Sharat Deorah HUF

Promoter group

229,0293.67

Kirtilaben Jayantilal Mehta

Public

195,0003.13

Samir Jitendra Javeri

Public

161,5332.59

Shikha Lohia

Public

96,1261.54

Ravi Parimal Shah

Public

90,5711.45

Siddhartha Deorah HUF

Promoter group

5,4560.09

Competitive Landscape

Key Competitors

CompetitorSegment overlapScale / positioningData status

Aarti Drugs Ltd (India)

Metformin HCl API (major global producer); backward-integrated into amines

FY2026 consolidated revenue INR 2,567.7 crore; PAT INR 194.9 crore

Verified (company/FilingReader, May 2026)

Wanbury Ltd (India)

Metformin HCl & Metformin DC API (core product alongside sertraline)

FY2026 revenue INR 650.3 crore; EBITDA INR 107.7 crore; PAT INR 66.1 crore

Verified (DSIJ/Sahi, 2026)

Vistin Pharma ASA (Norway)

Pure-play premium metformin API incl. DC grades

2025 revenue NOK 452 million; EBITDA NOK 115 million; ~6,000 MT annualised production

Verified (company release Feb 2026)

Granules India Ltd (India)

Metformin API and FDF (high-volume molecules)

——

Harman Finochem Ltd (India)

Metformin and anti-diabetic APIs

Unlisted; figures not publicly disclosed

—

USV Pvt Ltd (India)

Metformin API and diabetes formulations (integrated)

Unlisted; figures not publicly disclosed

—

Shouguang Fukang Pharmaceutical (China)

Large-volume metformin API

——

Chinese metformin producers (multiple)

Cost-leading volume supply

Coherent MI notes heavy global dependence on China/India API supply

Qualitative

Supriya Lifescience Ltd (India)

Chlorpheniramine maleate API

——

Indian domestic diabetes FDF makers (various)

Metformin + gliptin/gliflozin combination tablets

Fragmented; highly competitive

Qualitative

“—” = not publicly disclosed.

Peer Comparison FY2026

MetricAuro Laboratories (FY2026)Aarti Drugs (FY2026)Wanbury (FY2026)Vistin Pharma (CY2025)

Revenue (local currency)

INR 30.74 cr

INR 2,567.7 cr

INR 650.3 cr

NOK 452 M

Revenue growth YoY (%)

60.778.55

EBITDA margin (%)

33.212.116.625.4

Net margin (%)

11.57.610.216.5

Balance sheet

Net debt ~INR 62 cr; D/E 1.37×

—

Refinanced Jun 2026 (sub-10% cost)

Net cash NOK 16 M; equity ratio 75%

Recent Developments

Industry-context developments affecting Auro: * Aarti Drugs commissioned its Sayakha amines facility (Sep 2025) to self-supply metformin intermediates, reaching 1,000 tonnes/month in March 2026; Wanbury received nine US FDA "No DMF Deficiency" letters for Metformin HCl in July–August 2026 and commercialised Metformin DC in Saudi Arabia; Vistin Pharma reported record 2025 volumes but lower global metformin prices. Each intensifies competition in Auro's core molecule.

Company Snapshot

$3.5M

Revenue

1992

Founded

District Palghar, India

Headquarters

SWOT Analysis

Strengths

  • Regulated-market credentials: EDQM CEPs for Metformin HCl (since Sep 2006) and Chlorphenamine Maleate; EU-GMP and WHO-GMP since 2005 (PharmaSource; IIFL).
  • Renewed WHO-GMP: certificate received Nov 2025, valid to 30 Sep 2028 (ScanX), securing tender/emerging-market eligibility for three years.
  • Export franchise: exports account for 70–75% of revenue across Europe, Africa, SE Asia and LatAm (Crisil, Aug 2025).
  • New capacity in place: capacity raised from 1,260 MT to 2,100 MT p.a. on Aug 2025 commissioning (Acuite); construction-in-progress fell from INR 564.8 M to INR 144.8 M as assets were capitalised (S&P FY2026).
  • Margin recovery: Q2 FY2026 OPM 26.6% (vs. 23.2%) and ~31% 9MFY2026 operating margin (Acuite), indicating new-block economics are superior to the legacy unit.
  • Committed, unpledged promoters: 52.18% promoter holding with zero pledge and no change through Mar 2026 (MarketsMojo); Crisil expected promoters to support via equity/unsecured loans if needed.

Weaknesses

  • Single-molecule dependence: nearly 80% of revenue from Metformin HCl (Crisil).
  • Sub-scale: FY2026 revenue INR 30.74 crore is ~43% below FY2024's INR 53.6 crore despite a ~4× larger fixed-asset base.
  • Leverage: total debt INR 633 M vs. equity INR 463 M (D/E 1.37×); net debt/EBITDA ~6.1× (S&P FY2026).
  • Weak coverage: EBIT/interest 1.87× in FY2026 (S&P); Simply Wall St shows 1.4× TTM coverage.
  • Working-capital intensity: gross current assets of 400–405 days and receivables of 175–180 days at Mar 2025; bank lines near fully utilised (Crisil).
  • Thin disclosure and governance depth: no earnings calls, no investor presentations, no disclosed R&D; CFO resigned May 2026 without a disclosed successor; Chair and MD combined.

Opportunities

  • Utilisation upside: at FY2024 asset turnover (0.63×) the FY2026 asset base implies revenue capacity of ~INR 76 crore, ~2.5× FY2026.
  • Value-added forms: DC and combination granules and a 1 bn-tablet FDF facility (CPHI 2026) offer higher realisations than plain API.
  • Gliptin/gliflozin FDC generics wave: company already markets metformin combinations with gliptins and gliflozins.
  • Market growth: metformin API volumes forecast to grow ~4–6% annually (Vistin/IDF; QYResearch 6.3% value CAGR).
  • New geographies: existing registrations in S. Korea, Taiwan, Malaysia (CPHI China profile) plus active 2026 marketing in Korea, Thailand, Saudi Arabia.
  • Deleveraging path: Acuite expects INR 6–15 crore annual accruals vs. INR 2–6 crore repayments FY2026–FY2027, which, if achieved, would begin to reduce net debt.

Threats

  • Price erosion: Vistin reported lower global metformin prices in Q4 2025 despite record volumes.
  • Integrated competitors: Aarti Drugs' Sayakha facility reached 1,000 tonnes/month in Mar 2026, cutting its metformin intermediate costs.
  • Regulated-market competition: Wanbury received nine US FDA "No DMF Deficiency" letters (Jul–Aug 2026) and launched Metformin DC in Saudi Arabia and Mexico.
  • Geopolitics: Middle East disruption depressed 9MFY2026 revenue (Acuite).
  • Input/FX volatility: reliance on overseas raw-material vendors and export pricing (Acuite; Crisil).
  • Credit stress: Crisil's downgrade trigger (NCA/repayment ≤1.1×) and rating already at BB+ (sub-investment grade) — further slippage would raise funding costs.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
May 2025Q4 FY2025 results: net profit down 83% YoY to INR 0.39 crore; FY2025 PAT INR 1.84 crore (-76%)Trough of expansion-related disruption
9 Jul 2025Reg. 30 disclosure of completion of expansion projectCapex phase ends
7 Aug 2025Board meeting notice for Q1 FY2026 resultsRoutine
14 Aug 2025Q1 FY2026: net loss INR 0.11 crore; sales down 51.6% to INR 2.77 croreRamp-up slower than hoped
14 Aug 2025Company Secretary resignation disclosedCompliance personnel turnover
Aug 2025New production block commissioned; capacity to 2,100 MT p.a. (Acuite)Key operational milestone
23 Aug 2025Statutory auditor Kothari Jain & Associates resigns; B.L. Dasharda & Associates appointedAuditor change mid-cycle; no disagreements stated
23 Aug 2025GMJ & Associates appointed secretarial auditor; Kavita Sharma re-appointed; Padma Tapariya named CSGovernance refresh
25 Aug 2025Crisil reaffirms BB+/Stable, A4+ and withdraws ratings on company requestRating agency switch
25 Sep 202536th AGM (video-conference) approves auditor, director re-appointmentsRoutine
1 Oct 2025New CS takes officeRoutine
12–13 Nov 2025Q2 FY2026: sales +185% YoY to INR 8.84 crore; net profit INR 0.72 crore (+100%); OPM 26.6%First evidence of ramp-up
13 Nov 2025WHO-GMP certificate for API facility, valid to 30 Sep 2028; stock rallied on the newsSupports tender/emerging-market access
28 Jan 2026Board meeting notice for Q3 FY2026Routine
5 Feb 2026Q3 FY2026: revenue up ~206% YoY; net profit INR 1.95 crore vs INR 0.05 croreBest quarter post-expansion
26 Mar 2026Trading window closure from 1 Apr 2026Routine
14 Apr 2026Acuite assigns BB+/Stable and A4+ on INR 79.80 crore facilities; flags 9MFY2026 revenue of INR 22.25 crore below expectations due to Middle EastNew rating anchor; larger debt lines
14 Apr 2026Reg. 74(5) certificate for Q4 FY2026 (8,200 shares dematerialised)Routine
26 May 2026Board meeting notice for FY2026 results (29 May)Routine
28–29 May 2026CFO resigns effective 28 May 2026Governance monitorable
29 May 2026FY2026 audited results: revenue INR 30.74 crore (+61%), PBT INR 4.81 crore, PAT INR 3.53 crore, EPS INR 5.67; Q4 net profit INR 0.97 crore (+149% YoY)Recovery confirmed but sub-FY2024
Jun 2026Exhibits at CPHI China, ShanghaiMarketing
30 Jun 2026Kiran Kulkarni re-appointed WTD for 3 yearsContinuity
8–10 Jul 2026Exhibits at CPHI South-East Asia, BangkokMarketing
15 Jul 202637th AGM scheduled for 11 Aug 2026Routine
11 Aug 202637th AGM held; scrutiniser report filedRoutine
14 Aug 2026Q1 FY2027 results: net profit INR 1.05 crore (vs. -0.11 crore), net margin ~12%Profitable run-rate sustained
25–27 Aug 2026Exhibits at CPHI Korea, SeoulKorea registration leverage
6–8 Oct 2026Exhibits at CPHI Milan; markets 7,200 MT metformin and 1 bn-tablet FDF capacityCapacity claims well above rating-agency figure
UpcomingQ2 FY2027 results due by mid-Nov 2026; CPHI India (23–25 Nov) and CPHI Middle East (14–16 Dec)Near-term catalysts

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

3 charts
Income Statement: Revenue & Gross Profit: Revenue fell from INR 508.7 Mn in FY2022 to INR 307.4 Mn in FY2026.
Auro Laboratories Limited — Income Statement: Revenue & Gross Profit
Series (INR Mn)FY2022FY2023FY2024FY2025FY2026
Revenue508.7528.9536.4191.2307.4
Cost of revenue335.5360.7269.592.863.3
Gross profit173.2168.3266.998.4244.1

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. BSE corporate filings: board meeting outcomes (13 Feb 2023; 11 Nov 2024; 12 Nov 2025) and change-in-directors disclosure (28 Jun 2024) · bseindia.com · bseindia.com · bsmedia.business-standard.com
  2. Auro Laboratories Annual Report 2009-10 (BSE) (bseindia.com)
  3. Auro Laboratories Annual Report 2024-25 (Value Research mirror) (valueresearchonline.com)
  4. Crisil Ratings rationale, 25 Aug 2025 — 25_ 2025_RR_376578.html (crisil.com)
  5. Acuite rating assignment (ScanX), 14 Apr 2026 (scanx.trade)
  6. Management and auditor changes (ScanX), 23 Aug 2025 (scanx.trade)
  7. ScanX company newsfeed · scanx.trade · scanx.trade
  8. StockAnalysis.com (S&P Global Market Intelligence data): income statement, balance sheet, cash flow · stockanalysis.com · stockanalysis.com
  9. Business Standard / Capital Market, Q2 FY2026 results (business-standard.com)
  10. Tickertape quarterly news (tickertape.in)
  11. Fyers P&L summary (fyers.in)
  12. Bajaj Broking quarterly net profit/margins (bajajbroking.in)
  13. Bajaj Finserv shareholding (bajajfinserv.in)
  14. MarketsMojo shareholding, management, company CV · marketsmojo.motilaloswal.com
  15. Screener.in · screener.in
  16. Simply Wall St · simplywall.st
  17. IIFL company summary · indiainfoline.com
  18. Trendlyne bulk/block deals (client.trendlyne.com)
  19. Nirmal Bang company page (nirmalbang.com)
  20. Sharekhan company page (sharekhan.com)
  21. FinancialFilings.com filings index (financialfilings.com)
  22. PharmaCompass; PharmaSource; PharmaOffer directories · pharmasource.global · pharmaoffer.com
  23. CPHI Online exhibitor profiles (2026) · cphi-online.com
  24. Aarti Drugs FY2026 results (FilingReader; Indian Pharma Post) · indianpharmapost.com
  25. Wanbury FY2026 and metformin DMF news (DSIJ; Sahi) · sahi.com
  26. Vistin Pharma Q4/FY2025 results and calls · filingreader.com · gurufocus.com
  27. Metformin API market reports · intelmarketresearch.com · coherentmi.com

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.